Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | FPR3 | P25089 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29619014 | 0.91 | NPC1 (0.42) | F2RL3ALOX5APFEN1FPR3FPR2 | |
| SCHEMBL29619065 | 0.90 | F2RL3 (0.38) | F2RL3ALOX5APFEN1GPR119EPHA2 | |
| SCHEMBL29619024 | 0.88 | ALOX5AP (0.43) | F2RL3ALOX5APFEN1GPR119EPHA2 | |
| SCHEMBL29619089 | 0.86 | MCHR1 (0.37) | F2RL3ALOX5APFEN1GPR119EPHA2 | |
| SCHEMBL29619027 | 0.85 | NPC1 (0.42) | GPR119NPC1 | |
| SCHEMBL29619033 | 0.83 | F2RL3 (0.38) | F2RL3ALOX5APFEN1GPR119ALDH1A1 | |
| SCHEMBL31663763 | 0.80 | NPC1 (0.44) | F2RL3ALOX5APFEN1FPR3FPR2 | |
| SCHEMBL31663765 | 0.80 | NPC1 (0.44) | F2RL3ALOX5APFEN1FPR3FPR2 | |
| SCHEMBL31663788 | 0.80 | NPC1 (0.44) | F2RL3ALOX5APFEN1FPR3FPR2 | |
| SCHEMBL31663811 | 0.79 | FPR3 (0.39) | F2RL3ALOX5APFEN1EPHA2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4236942-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022093850-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | HTR2A, HTR5A, HTR1A | F2RL3 1301/4885ALOX5AP 177/4885FEN1 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.